Market Access
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Access to medicines have persisting and systemic differences across the globe and within countries. ...
Recent Trends Impacting Funding and Access to Rare Disease Therapies
Funding and access are not new topics of conversation in the rare disease space. ...
New Research Reveals Three Ways Pharma Can Better Prioritize Payer Audiences
The pandemic had a huge impact on the way population health decision-makers (PHDMs) navigate ...
Biosimilars Market Set for Biggest Year Yet in 2023
In perhaps the most significant moment for the U.S. biosimilars market to date, the ...
Innovative Contracting in Europe—A Double Hurdle to Value?
In many markets around the world, but particularly in Europe, there have always been ...
ISPOR 2023 Plenaries and Speakers Announced
ISPOR—The Professional Society for Health Economics and Outcomes Research announced the plenary sessions and speakers ...
Market Access Disruption—How New Generic Players Are Changing the Game
For the last 30 years or so, the pharmaceutical landscape has been dominated by ...
Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs
It’s never too early in the research and development (R&D) process to identify and ...
Making Sense of the Latest Changes to the Market Access Landscape
No one has ever described the pharma market access landscape as simple or easy ...
Two Key Questions About Payer Strategies in 2023
PM360 asked experts in developing market access strategies about how the Inflation Reduction Act ...
The Focus and Challenges for Access in Emerging Markets
When comparing the challenges presented in emerging markets with more mature markets, the obvious ...
Identifying Copay Accumulator Impact: Winning the Race for Patient Access
The pharmaceutical supply chain is so complex that it provides the perfect camouflage for ...
Data Doesn’t Cut It—Payer Engagement Requires a Humanistic Approach
A drug’s ability to reach the market is essential; however, pharma manufacturers have struggled ...
